Frontiers in endocrinology · 2025
Thermal ablation for ata intermediate-risk papillary thyroid carcinoma: efficacy and safety outcomes in a retrospective cohort.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cong Tian-Hao, Wei Ying, Zhao Zhen-Long, Cao Shi-Liang, Yu Na, Wu Jie, Zhou Xin-Yi, Zhao Han-Xiao, Peng Li-Li, Li Yan, Yu Ming-An
Аннотация
PURPOSE: To evaluate the efficacy and safety of thermal ablation (TA) for ATA intermediate-risk papillary thyroid carcinoma (PTC).
METHODS AND MATERIALS: This retrospective study analyzed ATA intermediate-risk PTC (either ultrasound extrathyroidal extension or cervical lymph node < 3cm metastasis) patients treated with TA at China-Japan Friendship Hospital between April 2018 and December 2023. Outcomes included technical success, recurrence-free survival (RFS), and complications. Multi-Cox regression identified prognostic factors.
RESULTS: A total of 113 people were included. TA demonstrated 100% technical success and complete ablation rates. 18 patients (15.9%) had developed tumor recurrence. The 1-, 3-, and 5-year RFS rates were 95.6%, 83.7%, and 79.8%, respectively. Metastatic lymph node diameter independently predicted progression (HR:3.20, p<0.05). Complications occurred in 21.2% of cases, with 1.8% permanent vocal cord paralysis.
CONCLUSIONS: TA shows promising efficacy and safety for selected ATA intermediate-risk PTC patients, with lymph node size as a key prognostic factor.
METHODS AND MATERIALS: This retrospective study analyzed ATA intermediate-risk PTC (either ultrasound extrathyroidal extension or cervical lymph node < 3cm metastasis) patients treated with TA at China-Japan Friendship Hospital between April 2018 and December 2023. Outcomes included technical success, recurrence-free survival (RFS), and complications. Multi-Cox regression identified prognostic factors.
RESULTS: A total of 113 people were included. TA demonstrated 100% technical success and complete ablation rates. 18 patients (15.9%) had developed tumor recurrence. The 1-, 3-, and 5-year RFS rates were 95.6%, 83.7%, and 79.8%, respectively. Metastatic lymph node diameter independently predicted progression (HR:3.20, p<0.05). Complications occurred in 21.2% of cases, with 1.8% permanent vocal cord paralysis.
CONCLUSIONS: TA shows promising efficacy and safety for selected ATA intermediate-risk PTC patients, with lymph node size as a key prognostic factor.